| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 50 | 2024 | 5696 | 3.220 |
Why?
|
| Antineoplastic Agents | 71 | 2023 | 13639 | 2.930 |
Why?
|
| Pyrazines | 12 | 2024 | 1204 | 2.660 |
Why?
|
| Neoplasms | 69 | 2024 | 22343 | 2.590 |
Why?
|
| Pyrazoles | 19 | 2021 | 2029 | 2.480 |
Why?
|
| Cyclin-Dependent Kinases | 14 | 2024 | 661 | 2.360 |
Why?
|
| HSP90 Heat-Shock Proteins | 14 | 2021 | 422 | 2.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 12 | 2024 | 561 | 2.090 |
Why?
|
| Cyclin-Dependent Kinase 6 | 9 | 2019 | 352 | 2.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2024 | 11872 | 2.000 |
Why?
|
| Piperidines | 15 | 2020 | 1662 | 1.810 |
Why?
|
| Maximum Tolerated Dose | 31 | 2021 | 895 | 1.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 48 | 2023 | 5389 | 1.660 |
Why?
|
| Ovarian Neoplasms | 19 | 2024 | 4904 | 1.630 |
Why?
|
| Benzimidazoles | 6 | 2021 | 861 | 1.490 |
Why?
|
| Piperazines | 12 | 2024 | 2546 | 1.440 |
Why?
|
| BRCA1 Protein | 10 | 2024 | 1155 | 1.430 |
Why?
|
| Sulfonamides | 11 | 2024 | 1978 | 1.410 |
Why?
|
| Cystadenocarcinoma, Serous | 5 | 2021 | 480 | 1.390 |
Why?
|
| Pyrimidines | 13 | 2020 | 3047 | 1.330 |
Why?
|
| Lung Neoplasms | 62 | 2023 | 13486 | 1.330 |
Why?
|
| CDC2 Protein Kinase | 6 | 2018 | 212 | 1.320 |
Why?
|
| Cisplatin | 9 | 2021 | 1656 | 1.290 |
Why?
|
| Phthalazines | 6 | 2024 | 397 | 1.260 |
Why?
|
| Azetidines | 3 | 2020 | 151 | 1.250 |
Why?
|
| Isoindoles | 2 | 2020 | 36 | 1.190 |
Why?
|
| Isoxazoles | 5 | 2024 | 233 | 1.160 |
Why?
|
| Pyridines | 16 | 2020 | 2888 | 1.150 |
Why?
|
| Pyrimidinones | 4 | 2024 | 385 | 1.060 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2024 | 5334 | 1.030 |
Why?
|
| DNA Damage | 14 | 2023 | 2464 | 1.020 |
Why?
|
| Azepines | 2 | 2020 | 329 | 0.990 |
Why?
|
| Deoxycytidine | 9 | 2024 | 886 | 0.960 |
Why?
|
| Flavonoids | 10 | 2013 | 447 | 0.940 |
Why?
|
| Quinazolines | 17 | 2024 | 1367 | 0.920 |
Why?
|
| DNA Repair | 16 | 2024 | 2048 | 0.900 |
Why?
|
| Aniline Compounds | 5 | 2024 | 1079 | 0.890 |
Why?
|
| Enzyme Inhibitors | 15 | 2018 | 3721 | 0.880 |
Why?
|
| Benzamides | 3 | 2020 | 1375 | 0.870 |
Why?
|
| Food-Drug Interactions | 3 | 2018 | 26 | 0.830 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2024 | 1765 | 0.830 |
Why?
|
| Nuclear Proteins | 14 | 2023 | 5794 | 0.820 |
Why?
|
| Drug Administration Schedule | 18 | 2021 | 4850 | 0.810 |
Why?
|
| bcl-X Protein | 1 | 2024 | 412 | 0.800 |
Why?
|
| Cell Cycle Proteins | 16 | 2023 | 3439 | 0.770 |
Why?
|
| Pyridones | 3 | 2024 | 818 | 0.770 |
Why?
|
| Proto-Oncogene Proteins c-met | 9 | 2019 | 562 | 0.750 |
Why?
|
| Mutation | 32 | 2024 | 30220 | 0.750 |
Why?
|
| Aminopyridines | 5 | 2023 | 576 | 0.750 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2023 | 1762 | 0.740 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2023 | 2426 | 0.730 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2023 | 481 | 0.710 |
Why?
|
| Indazoles | 4 | 2020 | 306 | 0.700 |
Why?
|
| Cell Cycle | 15 | 2024 | 2925 | 0.690 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2013 | 238 | 0.680 |
Why?
|
| Cell Line, Tumor | 45 | 2024 | 17082 | 0.680 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 12 | 2021 | 1621 | 0.680 |
Why?
|
| Quinolines | 11 | 2015 | 769 | 0.660 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2020 | 10740 | 0.660 |
Why?
|
| Apoptosis | 17 | 2024 | 9507 | 0.660 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 3601 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 5 | 2023 | 635 | 0.650 |
Why?
|
| Triazoles | 3 | 2013 | 902 | 0.630 |
Why?
|
| Anilides | 4 | 2018 | 413 | 0.620 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1434 | 0.620 |
Why?
|
| Xenograft Model Antitumor Assays | 20 | 2024 | 3605 | 0.600 |
Why?
|
| Camptothecin | 3 | 2016 | 599 | 0.580 |
Why?
|
| DNA Replication | 5 | 2024 | 1426 | 0.580 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2024 | 8619 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 7 | 2023 | 5453 | 0.570 |
Why?
|
| S Phase | 4 | 2009 | 424 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2006 | 185 | 0.560 |
Why?
|
| Benzoquinones | 5 | 2013 | 198 | 0.560 |
Why?
|
| Cyclins | 2 | 2017 | 604 | 0.550 |
Why?
|
| Humans | 208 | 2024 | 766432 | 0.550 |
Why?
|
| Aged | 90 | 2024 | 171234 | 0.540 |
Why?
|
| Carcinoma | 3 | 2023 | 2323 | 0.530 |
Why?
|
| Immunoconjugates | 3 | 2020 | 976 | 0.520 |
Why?
|
| Lactams, Macrocyclic | 5 | 2013 | 319 | 0.510 |
Why?
|
| Poly(ADP-ribose) Polymerases | 5 | 2023 | 428 | 0.510 |
Why?
|
| Aged, 80 and over | 46 | 2024 | 59538 | 0.500 |
Why?
|
| Middle Aged | 92 | 2024 | 223127 | 0.490 |
Why?
|
| Triazines | 2 | 2015 | 311 | 0.490 |
Why?
|
| Female | 120 | 2024 | 396354 | 0.490 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2014 | 92 | 0.490 |
Why?
|
| Indoles | 5 | 2024 | 1832 | 0.490 |
Why?
|
| Oligopeptides | 2 | 2020 | 1195 | 0.490 |
Why?
|
| Quinoxalines | 2 | 2014 | 296 | 0.480 |
Why?
|
| TOR Serine-Threonine Kinases | 9 | 2021 | 2059 | 0.470 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 9 | 2016 | 703 | 0.470 |
Why?
|
| Organic Chemicals | 1 | 2015 | 211 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 2947 | 0.460 |
Why?
|
| Morpholines | 2 | 2015 | 584 | 0.460 |
Why?
|
| Treatment Outcome | 47 | 2024 | 65202 | 0.450 |
Why?
|
| Transforming Growth Factor beta | 3 | 2019 | 1997 | 0.450 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2014 | 330 | 0.440 |
Why?
|
| Adult | 78 | 2024 | 223253 | 0.440 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2010 | 68 | 0.430 |
Why?
|
| DNA, Single-Stranded | 2 | 2024 | 351 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2023 | 4521 | 0.400 |
Why?
|
| Male | 95 | 2024 | 363975 | 0.400 |
Why?
|
| Administration, Oral | 11 | 2021 | 4014 | 0.400 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 480 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2825 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 4652 | 0.370 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2023 | 1058 | 0.370 |
Why?
|
| Neoplasm Staging | 17 | 2020 | 11217 | 0.370 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2012 | 678 | 0.370 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 338 | 0.360 |
Why?
|
| cdc25 Phosphatases | 1 | 2011 | 60 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 308 | 0.360 |
Why?
|
| Signal Transduction | 22 | 2024 | 23611 | 0.360 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2023 | 1609 | 0.350 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 3943 | 0.350 |
Why?
|
| Phosphorylation | 15 | 2020 | 8300 | 0.350 |
Why?
|
| Area Under Curve | 9 | 2015 | 1638 | 0.350 |
Why?
|
| Hydroxamic Acids | 3 | 2013 | 483 | 0.340 |
Why?
|
| MAP Kinase Signaling System | 3 | 2020 | 1490 | 0.340 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2012 | 776 | 0.340 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2006 | 68 | 0.320 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 459 | 0.320 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 286 | 0.320 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1998 | 0.310 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 6361 | 0.310 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 616 | 0.310 |
Why?
|
| GTP Phosphohydrolases | 2 | 2024 | 525 | 0.300 |
Why?
|
| E2F1 Transcription Factor | 2 | 2006 | 182 | 0.300 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 4888 | 0.300 |
Why?
|
| Gene Rearrangement | 5 | 2019 | 1142 | 0.290 |
Why?
|
| Food | 2 | 2011 | 764 | 0.290 |
Why?
|
| Transcription Factors | 7 | 2023 | 12147 | 0.290 |
Why?
|
| Animals | 58 | 2024 | 168887 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 4049 | 0.280 |
Why?
|
| Infusions, Intravenous | 7 | 2020 | 2227 | 0.270 |
Why?
|
| Retinoblastoma Protein | 7 | 2010 | 668 | 0.270 |
Why?
|
| G1 Phase | 4 | 2006 | 403 | 0.270 |
Why?
|
| Membrane Proteins | 3 | 2019 | 7866 | 0.270 |
Why?
|
| Quinones | 2 | 2005 | 79 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2024 | 997 | 0.260 |
Why?
|
| Mice | 45 | 2024 | 81863 | 0.260 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3702 | 0.260 |
Why?
|
| Phenylurea Compounds | 3 | 2019 | 536 | 0.260 |
Why?
|
| Proteins | 1 | 2020 | 6002 | 0.250 |
Why?
|
| Doxorubicin | 1 | 2012 | 2228 | 0.250 |
Why?
|
| Drug Synergism | 4 | 2019 | 1755 | 0.250 |
Why?
|
| Drug Design | 1 | 2010 | 1042 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2014 | 2185 | 0.240 |
Why?
|
| Breast Neoplasms | 10 | 2024 | 21157 | 0.240 |
Why?
|
| RNA, Small Interfering | 6 | 2016 | 3424 | 0.240 |
Why?
|
| Pyridinium Compounds | 2 | 2016 | 80 | 0.240 |
Why?
|
| Glycoside Hydrolases | 1 | 2024 | 135 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 547 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2020 | 1243 | 0.230 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2004 | 111 | 0.220 |
Why?
|
| BRCA2 Protein | 3 | 2020 | 802 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2022 | 2880 | 0.220 |
Why?
|
| Mucin-1 | 2 | 2023 | 536 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 9401 | 0.210 |
Why?
|
| Stress, Physiological | 1 | 2010 | 1404 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 904 | 0.210 |
Why?
|
| Receptor, erbB-2 | 7 | 2013 | 2597 | 0.210 |
Why?
|
| MicroRNAs | 1 | 2019 | 3788 | 0.210 |
Why?
|
| DNA-Binding Proteins | 7 | 2023 | 9611 | 0.210 |
Why?
|
| Genomics | 6 | 2023 | 5924 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 7 | 2017 | 9243 | 0.200 |
Why?
|
| Carboplatin | 6 | 2018 | 789 | 0.200 |
Why?
|
| Carrier Proteins | 5 | 2011 | 4924 | 0.200 |
Why?
|
| Chromones | 1 | 2022 | 148 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 11 | 2020 | 6105 | 0.200 |
Why?
|
| G2 Phase | 3 | 2011 | 134 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2012 | 454 | 0.190 |
Why?
|
| ras Proteins | 3 | 2017 | 1054 | 0.190 |
Why?
|
| Nausea | 4 | 2013 | 681 | 0.190 |
Why?
|
| Mitosis | 3 | 2021 | 1176 | 0.190 |
Why?
|
| Drug Monitoring | 3 | 2020 | 960 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2014 | 329 | 0.190 |
Why?
|
| Pyrroles | 3 | 2017 | 1120 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 2056 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2017 | 474 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2017 | 478 | 0.180 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.180 |
Why?
|
| Salvage Therapy | 3 | 2020 | 1274 | 0.180 |
Why?
|
| Genes, p16 | 2 | 2007 | 157 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2008 | 1608 | 0.180 |
Why?
|
| DNA, Neoplasm | 6 | 2010 | 1741 | 0.180 |
Why?
|
| Melanoma | 5 | 2023 | 5699 | 0.180 |
Why?
|
| Thiazoles | 3 | 2022 | 1528 | 0.180 |
Why?
|
| Platinum | 3 | 2020 | 219 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 2928 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 220 | 0.170 |
Why?
|
| Imidazoles | 1 | 2006 | 1168 | 0.170 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2020 | 124 | 0.170 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2022 | 111 | 0.170 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 6845 | 0.170 |
Why?
|
| Indolizines | 2 | 2016 | 29 | 0.160 |
Why?
|
| Cyclic N-Oxides | 2 | 2016 | 71 | 0.160 |
Why?
|
| Mice, SCID | 5 | 2020 | 2626 | 0.160 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2014 | 616 | 0.160 |
Why?
|
| Ataxia Telangiectasia | 1 | 2020 | 107 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2014 | 1405 | 0.160 |
Why?
|
| Drug Discovery | 3 | 2015 | 1065 | 0.160 |
Why?
|
| Fasting | 2 | 2018 | 1609 | 0.160 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 11059 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2011 | 5129 | 0.160 |
Why?
|
| Prognosis | 13 | 2021 | 29922 | 0.160 |
Why?
|
| Vomiting | 2 | 2012 | 652 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2020 | 604 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2013 | 2799 | 0.150 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 393 | 0.150 |
Why?
|
| Phenylenediamines | 1 | 2018 | 89 | 0.150 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 6962 | 0.150 |
Why?
|
| Cyclin D | 2 | 2015 | 70 | 0.140 |
Why?
|
| Gene Deletion | 1 | 2005 | 2668 | 0.140 |
Why?
|
| Oncogenes | 2 | 2021 | 1231 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 109 | 0.140 |
Why?
|
| Young Adult | 15 | 2023 | 59928 | 0.140 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 327 | 0.140 |
Why?
|
| Clinical Trials as Topic | 7 | 2015 | 8042 | 0.140 |
Why?
|
| Half-Life | 2 | 2015 | 648 | 0.140 |
Why?
|
| Trifluridine | 1 | 2017 | 28 | 0.140 |
Why?
|
| Thymine | 1 | 2017 | 69 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 259 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2017 | 10092 | 0.130 |
Why?
|
| Gene Expression Profiling | 10 | 2018 | 9521 | 0.130 |
Why?
|
| Photophobia | 1 | 2017 | 77 | 0.130 |
Why?
|
| Histones | 3 | 2023 | 2591 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1105 | 0.130 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2016 | 193 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 2884 | 0.130 |
Why?
|
| Tumor Burden | 5 | 2015 | 1900 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2020 | 1617 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 3757 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 2251 | 0.130 |
Why?
|
| RNA, Viral | 4 | 1988 | 2867 | 0.130 |
Why?
|
| Receptor, erbB-3 | 1 | 2016 | 141 | 0.130 |
Why?
|
| Tissue Distribution | 3 | 2019 | 2275 | 0.130 |
Why?
|
| Influenza A virus | 3 | 1988 | 455 | 0.120 |
Why?
|
| Cyclopentanes | 1 | 2015 | 87 | 0.120 |
Why?
|
| Neutropenia | 3 | 2016 | 894 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 577 | 0.120 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2015 | 94 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 625 | 0.120 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 89 | 0.120 |
Why?
|
| Osteosarcoma | 3 | 2006 | 908 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 739 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 17 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 958 | 0.120 |
Why?
|
| Pyrrolidines | 1 | 2017 | 338 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 3 | 2011 | 361 | 0.120 |
Why?
|
| Keratoacanthoma | 1 | 2015 | 33 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2021 | 2078 | 0.120 |
Why?
|
| Fatigue | 2 | 2012 | 1554 | 0.120 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 125 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 2010 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2020 | 2446 | 0.120 |
Why?
|
| Cyclin D1 | 4 | 2016 | 454 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2013 | 3508 | 0.120 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2014 | 85 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 513 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 2055 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 110 | 0.110 |
Why?
|
| Keratitis | 1 | 2017 | 241 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 800 | 0.110 |
Why?
|
| Cell Line, Transformed | 3 | 2006 | 861 | 0.110 |
Why?
|
| Gene Amplification | 6 | 2020 | 1088 | 0.110 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 329 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2013 | 1331 | 0.110 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 17 | 0.110 |
Why?
|
| Interferons | 3 | 2023 | 714 | 0.110 |
Why?
|
| Resorcinols | 1 | 2013 | 41 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2016 | 5021 | 0.110 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 39283 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 596 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 426 | 0.100 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 324 | 0.100 |
Why?
|
| Rad51 Recombinase | 1 | 2013 | 191 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 125 | 0.100 |
Why?
|
| Valine | 1 | 2014 | 410 | 0.100 |
Why?
|
| Biostatistics | 1 | 2014 | 162 | 0.100 |
Why?
|
| Oleanolic Acid | 1 | 2012 | 43 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 3664 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 741 | 0.100 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 67 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 168 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 419 | 0.100 |
Why?
|
| Depsipeptides | 1 | 2012 | 95 | 0.100 |
Why?
|
| Cell Death | 3 | 2012 | 1676 | 0.100 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 7607 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2018 | 2930 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2021 | 2854 | 0.090 |
Why?
|
| Virus Replication | 3 | 1988 | 2457 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 428 | 0.090 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 269 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2012 | 2108 | 0.090 |
Why?
|
| Ki-67 Antigen | 3 | 2015 | 629 | 0.090 |
Why?
|
| Biological Availability | 1 | 2011 | 387 | 0.090 |
Why?
|
| Sample Size | 1 | 2014 | 844 | 0.090 |
Why?
|
| Antiemetics | 1 | 2012 | 187 | 0.090 |
Why?
|
| Genes, bcl-2 | 1 | 2011 | 119 | 0.090 |
Why?
|
| Genes, cdc | 1 | 2011 | 113 | 0.090 |
Why?
|
| Cell Line | 7 | 2020 | 15563 | 0.090 |
Why?
|
| Substrate Specificity | 2 | 2012 | 1749 | 0.090 |
Why?
|
| Sirolimus | 4 | 2013 | 1541 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2013 | 372 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2016 | 6212 | 0.090 |
Why?
|
| Protein Stability | 1 | 2012 | 577 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2006 | 316 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2013 | 376 | 0.090 |
Why?
|
| DNA Mutational Analysis | 4 | 2020 | 4114 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 307 | 0.080 |
Why?
|
| Mutagens | 1 | 2010 | 181 | 0.080 |
Why?
|
| Survival Rate | 7 | 2023 | 12825 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2009 | 107 | 0.080 |
Why?
|
| Cell Proliferation | 7 | 2024 | 10438 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2014 | 2511 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 170 | 0.080 |
Why?
|
| Cohort Studies | 7 | 2023 | 41703 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2014 | 3186 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 496 | 0.080 |
Why?
|
| Mice, Nude | 6 | 2016 | 3610 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 5502 | 0.080 |
Why?
|
| Ifosfamide | 2 | 2023 | 233 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1697 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 13410 | 0.080 |
Why?
|
| Naphthyridines | 1 | 2011 | 184 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2009 | 205 | 0.080 |
Why?
|
| Genes, Viral | 2 | 1987 | 654 | 0.080 |
Why?
|
| Bone Neoplasms | 3 | 2006 | 2561 | 0.080 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.080 |
Why?
|
| Disease Models, Animal | 7 | 2018 | 18322 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2023 | 4749 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 385 | 0.080 |
Why?
|
| Dideoxynucleosides | 1 | 2008 | 135 | 0.080 |
Why?
|
| Alanine | 1 | 2011 | 613 | 0.080 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2007 | 17 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 1424 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 10263 | 0.070 |
Why?
|
| Paclitaxel | 5 | 2010 | 1727 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4356 | 0.070 |
Why?
|
| Kidney Neoplasms | 3 | 2014 | 4282 | 0.070 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 88 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1851 | 0.070 |
Why?
|
| NIH 3T3 Cells | 2 | 2008 | 654 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 751 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 790 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2016 | 1715 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2825 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2007 | 109 | 0.070 |
Why?
|
| RNA Polymerase II | 2 | 2013 | 549 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 5860 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2023 | 2839 | 0.070 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 161 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1163 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2010 | 876 | 0.060 |
Why?
|
| Quinazolinones | 1 | 2007 | 219 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 1227 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6612 | 0.060 |
Why?
|
| Thrombocytopenia | 3 | 2013 | 1172 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 1987 | 148 | 0.060 |
Why?
|
| Cell Nucleus | 4 | 2012 | 2869 | 0.060 |
Why?
|
| Gene Duplication | 1 | 2006 | 315 | 0.060 |
Why?
|
| Positron-Emission Tomography | 5 | 2014 | 6545 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2013 | 1083 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2005 | 185 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2017 | 1419 | 0.060 |
Why?
|
| Disease Progression | 5 | 2012 | 13632 | 0.060 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 11094 | 0.060 |
Why?
|
| Eating | 1 | 2011 | 1538 | 0.060 |
Why?
|
| Leukemia | 1 | 2013 | 1521 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 3530 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 2693 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2016 | 24272 | 0.060 |
Why?
|
| RNA, Messenger | 8 | 2013 | 12788 | 0.060 |
Why?
|
| Transcription Factor DP1 | 1 | 2003 | 136 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 20706 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2016 | 52 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2004 | 284 | 0.050 |
Why?
|
| Drug Approval | 1 | 2010 | 820 | 0.050 |
Why?
|
| Proteomics | 2 | 2023 | 3906 | 0.050 |
Why?
|
| Gene Expression | 2 | 1999 | 7583 | 0.050 |
Why?
|
| Templates, Genetic | 3 | 1988 | 188 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 251 | 0.050 |
Why?
|
| E2F Transcription Factors | 1 | 2003 | 270 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6508 | 0.050 |
Why?
|
| Protein Binding | 2 | 2012 | 9315 | 0.050 |
Why?
|
| Lymphoma | 1 | 2012 | 1900 | 0.050 |
Why?
|
| Novobiocin | 1 | 2022 | 33 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8536 | 0.050 |
Why?
|
| Cell Division | 2 | 2007 | 4474 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 713 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1885 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1150 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2004 | 411 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 2329 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 2629 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 926 | 0.050 |
Why?
|
| Oximes | 1 | 2023 | 305 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3795 | 0.050 |
Why?
|
| Cytokines | 2 | 2013 | 7436 | 0.050 |
Why?
|
| Hypertension | 2 | 2012 | 8614 | 0.050 |
Why?
|
| Chromatin | 2 | 2023 | 2979 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2013 | 1966 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 2455 | 0.050 |
Why?
|
| Taxoids | 2 | 2016 | 665 | 0.050 |
Why?
|
| Mice, Transgenic | 5 | 2013 | 9539 | 0.050 |
Why?
|
| Pyridazines | 1 | 2022 | 199 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 1641 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2001 | 355 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2002 | 268 | 0.040 |
Why?
|
| Anemia | 2 | 2013 | 1514 | 0.040 |
Why?
|
| Cell Movement | 4 | 2013 | 5197 | 0.040 |
Why?
|
| Cyclin A | 1 | 1999 | 59 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3608 | 0.040 |
Why?
|
| Sarcoma | 1 | 2010 | 1802 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
| Purines | 1 | 2023 | 616 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.040 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 2534 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 4566 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 472 | 0.040 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1885 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 1129 | 0.040 |
Why?
|
| Cell Survival | 4 | 2011 | 5741 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 7207 | 0.040 |
Why?
|
| Genotype | 1 | 2013 | 13034 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 56 | 0.040 |
Why?
|
| Base Sequence | 4 | 2016 | 12412 | 0.040 |
Why?
|
| Bronchi | 1 | 2002 | 847 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2023 | 2590 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1997 | 23 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 614 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 616 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 1997 | 40 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 2007 | 1494 | 0.040 |
Why?
|
| Prednisone | 1 | 2022 | 1566 | 0.040 |
Why?
|
| Nervous System Neoplasms | 1 | 1997 | 91 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 2900 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 840 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 610 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2210 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2016 | 38 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2002 | 1646 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 753 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2013 | 1392 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 789 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2718 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Alleles | 1 | 2007 | 6894 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 5753 | 0.030 |
Why?
|
| Ovary | 1 | 2020 | 963 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2010 | 594 | 0.030 |
Why?
|
| Macrophages | 2 | 2020 | 5782 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 85 | 0.030 |
Why?
|
| DNA Primers | 2 | 2012 | 2824 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2010 | 3458 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2015 | 157 | 0.030 |
Why?
|
| Time Factors | 6 | 2012 | 40116 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 1660 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2021 | 1109 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 1997 | 563 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 774 | 0.030 |
Why?
|
| Caspases | 1 | 2017 | 881 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 1101 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3676 | 0.030 |
Why?
|
| Dimerization | 1 | 2016 | 882 | 0.030 |
Why?
|
| Acrylamides | 1 | 2016 | 260 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 304 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 1324 | 0.030 |
Why?
|
| Leukopenia | 1 | 2013 | 213 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 1995 | 746 | 0.030 |
Why?
|
| Methylation | 1 | 1995 | 1074 | 0.030 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 2012 | 18 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 517 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 1963 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 1612 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 2463 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 57 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3552 | 0.020 |
Why?
|
| Etoposide | 1 | 2013 | 638 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2019 | 4428 | 0.020 |
Why?
|
| Ondansetron | 1 | 2012 | 95 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2012 | 125 | 0.020 |
Why?
|
| Nitrophenols | 1 | 2012 | 169 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2470 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 637 | 0.020 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 189 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2020 | 81588 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2002 | 4164 | 0.020 |
Why?
|
| Phenotype | 3 | 2015 | 16721 | 0.020 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 488 | 0.020 |
Why?
|
| Stomatitis | 1 | 2013 | 271 | 0.020 |
Why?
|
| Tendons | 1 | 2015 | 556 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2012 | 253 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1103 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2340 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 1947 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 756 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17605 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 2038 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 591 | 0.020 |
Why?
|
| Recurrence | 2 | 2013 | 8478 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2010 | 113 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3689 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 6061 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1986 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2010 | 183 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11648 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1752 | 0.020 |
Why?
|
| Acetylation | 1 | 2012 | 1054 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 463 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 385 | 0.020 |
Why?
|
| Safety | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Adolescent | 3 | 2023 | 88898 | 0.020 |
Why?
|
| Cell Transdifferentiation | 1 | 2010 | 186 | 0.020 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 2143 | 0.020 |
Why?
|
| Viral Proteins | 2 | 1987 | 1801 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2021 | 54826 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5789 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1997 | 1704 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 419 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1262 | 0.020 |
Why?
|
| Drug Industry | 1 | 2014 | 791 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 540 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 184 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2010 | 579 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 36562 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2012 | 1019 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 1750 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 1317 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5302 | 0.020 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2007 | 96 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 4779 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 84 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1732 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1987 | 383 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2653 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 83 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 667 | 0.020 |
Why?
|
| Virion | 1 | 1988 | 428 | 0.020 |
Why?
|
| Viral Interference | 1 | 1985 | 11 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2900 | 0.020 |
Why?
|
| Lung | 2 | 2020 | 10064 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 4443 | 0.020 |
Why?
|
| Exons | 2 | 2006 | 2392 | 0.020 |
Why?
|
| Capsid | 1 | 1988 | 435 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 369 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 1027 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1071 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1987 | 527 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 4860 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 2006 | 425 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2007 | 711 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2012 | 1962 | 0.010 |
Why?
|
| Mutant Proteins | 1 | 2006 | 487 | 0.010 |
Why?
|
| Genes, ras | 1 | 2007 | 657 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 4400 | 0.010 |
Why?
|
| Biopsy | 1 | 2016 | 6778 | 0.010 |
Why?
|
| Age Factors | 2 | 2017 | 18395 | 0.010 |
Why?
|
| Retroviridae | 1 | 2007 | 845 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2004 | 84 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2012 | 18979 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 2391 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2782 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3093 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2012 | 2495 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 386 | 0.010 |
Why?
|
| RNA | 2 | 1995 | 2715 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 3736 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 1767 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2004 | 341 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5872 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 1742 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1987 | 1505 | 0.010 |
Why?
|
| Acute Disease | 1 | 2013 | 7240 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2010 | 1266 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 4167 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1988 | 3072 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2004 | 475 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 6217 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4270 | 0.010 |
Why?
|
| Point Mutation | 1 | 2007 | 1591 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1985 | 568 | 0.010 |
Why?
|
| Boston | 1 | 2014 | 9333 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4141 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9458 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 502 | 0.010 |
Why?
|
| Skin | 1 | 2015 | 4498 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 494 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 3585 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6306 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1525 | 0.010 |
Why?
|
| Patient Selection | 1 | 2011 | 4248 | 0.010 |
Why?
|
| Paxillin | 1 | 1999 | 86 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 5385 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4344 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 5750 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 2355 | 0.010 |
Why?
|
| Heart Rate | 1 | 2010 | 4190 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 1997 | 13 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1997 | 66 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 1425 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 3919 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1082 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12527 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2002 | 1179 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 321 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3824 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2004 | 1786 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 1997 | 228 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15390 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80668 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 22337 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2010 | 8532 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2008 | 3236 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 533 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1987 | 11919 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 5890 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 10379 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 14466 | 0.010 |
Why?
|
| Ligands | 1 | 1997 | 3276 | 0.010 |
Why?
|
| Research Design | 1 | 2004 | 6205 | 0.000 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1985 | 222 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 74828 | 0.000 |
Why?
|
| United States | 1 | 2011 | 72910 | 0.000 |
Why?
|